FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1563220956> ?p ?o ?g. }

• W1563220956 abstract "Background Sexual offending is a serious social problem, a public health issue, and a major challenge for social policy. Victim surveys indicate high incidence and prevalence levels and it is accepted that there is a high proportion of hidden sexual victimisation. Surveys report high levels of psychiatric morbidity in survivors of sexual offences. Biological treatments of sex offenders include antilibidinal medication, comprising hormonal drugs that have a testosterone‐suppressing effect, and non‐hormonal drugs that affect libido through other mechanisms. The three main classes of testosterone‐suppressing drugs in current use are progestogens, antiandrogens, and gonadotropin‐releasing hormone (GnRH) analogues. Medications that affect libido through other means include antipsychotics and serotonergic antidepressants (SSRIs). Objectives To evaluate the effects of pharmacological interventions on target sexual behaviour for people who have been convicted or are at risk of sexual offending. Search methods We searched CENTRAL (2014, Issue 7), Ovid MEDLINE, EMBASE, and 15 other databases in July 2014. We also searched two trials registers and requested details of unidentified, unpublished, or ongoing studies from investigators and other experts. Selection criteria Prospective controlled trials of antilibidinal medications taken by individuals for the purpose of preventing sexual offences, where the comparator group received a placebo, no treatment, or 'standard care', including psychological treatment. Data collection and analysis Pairs of authors, working independently, selected studies, extracted data, and assessed the risk of bias of included studies. We contacted study authors for additional information, including details of methods and outcome data. Main results We included seven studies with a total of 138 participants, with data available for 123. Sample sizes ranged from 9 to 37. Judgements for categories of risk of bias varied: concerns were greatest regarding allocation concealment, blinding of outcome assessors, and incomplete outcome data (dropout rates in the five community‐based studies ranged from 3% to 54% and results were usually analysed on a per protocol basis). Participant characteristics in the seven studies were heterogeneous, but the vast majority had convictions for sexual offences, ranging from exhibitionism to rape and child molestation. Six studies examined the effectiveness of three testosterone‐suppressing drugs: cyproterone acetate (CPA), ethinyl oestradiol (EO), and medroxyprogesterone acetate (MPA); a seventh evaluated two antipsychotics (benperidol and chlorpromazine). Five studies were placebo‐controlled; in two, MPA was administered as an adjunctive treatment to a psychological therapy (assertiveness training or imaginal desensitisation). Meta‐analysis was not possible due to heterogeneity of interventions, comparators, study designs, and other issues. The quality of the evidence overall was poor. In addition to methodological issues, much evidence was indirect. Primary outcome: recividism. Two studies reported recidivism rates formally. One trial of intramuscular MPA plus imaginal desensitisation (ID) found no reports of recividism at two‐year follow‐up for the intervention group (n = 10 versus one relapse within the group treated by ID alone). A three‐armed trial of oral MPA, alone or in combination with psychological treatment, reported a 20% rate of recidivism amongst those in the combined treatment arm (n = 15) and 50% of those in the psychological treatment only group (n = 12). Notably, all those in the 'oral MPA only' arm of this study (n = 5) dropped out immediately, despite treatment being court mandated. Two studies did not report recidivism rates as they both took place in one secure psychiatric facility from which no participant was discharged during the study, whilst another three studies did not appear directly to measure recividism but rather abnormal sexual activity alone. Secondary outcomes:The included studies report a variety of secondary outcomes. Results suggest that the frequency of self reported deviant sexual fantasies may be reduced by testosterone‐suppressing drugs, but not the deviancy itself (three studies). Where measured, hormonal levels, particularly levels of testosterone, tended to correlate with measures of sexual activity and with anxiety (two studies). One study measured anxiety formally; one study measured anger or aggression. Adverse events: Six studies provided information on adverse events. No study tested the effects of testosterone‐suppressing drugs beyond six to eight months and the cross‐over design of some studies may obscure matters (given the 'rebound effect' of some hormonal treatments). Considerable weight gain was reported in two trials of oral MPA and CPA. Side effects of intramuscular MPA led to discontinuation in some participants after three to five injections (the nature of these side effects was not described). Notable increases in depression and excess salivation were reported in one trial of oral MPA. The most severe side effects (extra‐pyramidal movement disorders and drowsiness) were reported in a trial of antipsychotic medication for the 12 participants in the study. No deaths or suicide attempts were reported in any study. The latter is important given the association between antilibidinal hormonal medication and mood changes. Authors' conclusions We found only seven small trials (all published more than 20 years ago) that examined the effects of a limited number of drugs. Investigators reported issues around acceptance and adherence to treatment. We found no studies of the newer drugs currently in use, particularly SSRIs or GnRH analogues. Although there were some encouraging findings in this review, their limitations do not allow firm conclusions to be drawn regarding pharmacological intervention as an effective intervention for reducing sexual offending. The tolerability, even of the testosterone‐suppressing drugs, was uncertain given that all studies were small (and therefore underpowered to assess adverse effects) and of limited duration, which is not consistent with current routine clinical practice. Further research is required before it is demonstrated that their administration reduces sexual recidivism and that tolerability is maintained. It is a concern that, despite treatment being mandated in many jurisdictions, evidence for the effectiveness of pharmacological interventions is so sparse and that no RCTs appear to have been published in two decades. New studies are therefore needed and should include trials with larger sample sizes, of longer duration, evaluating newer medications, and with results stratified according to category of sexual offenders. It is important that data are collected on the characteristics of those who refuse and those who drop out, as well as those who complete treatment." @default.
• W1563220956 created "2016-06-24" @default.
• W1563220956 creator A5014779796 @default.
• W1563220956 creator A5028903775 @default.
• W1563220956 creator A5070774015 @default.
• W1563220956 creator A5071946042 @default.
• W1563220956 creator A5079763431 @default.
• W1563220956 creator A5088792945 @default.
• W1563220956 date "2015-02-18" @default.
• W1563220956 modified "2023-10-13" @default.
• W1563220956 title "Pharmacological interventions for those who have sexually offended or are at risk of offending" @default.
• W1563220956 cites W10379942 @default.
• W1563220956 cites W1415179697 @default.
• W1563220956 cites W1500442275 @default.
• W1563220956 cites W1500581195 @default.
• W1563220956 cites W1563220956 @default.
• W1563220956 cites W1563990006 @default.
• W1563220956 cites W158909518 @default.
• W1563220956 cites W1595123158 @default.
• W1563220956 cites W1734889242 @default.
• W1563220956 cites W1764744242 @default.
• W1563220956 cites W178199481 @default.
• W1563220956 cites W1833357926 @default.
• W1563220956 cites W190707400 @default.
• W1563220956 cites W1943406712 @default.
• W1563220956 cites W1947804209 @default.
• W1563220956 cites W1952442899 @default.
• W1563220956 cites W1969408106 @default.
• W1563220956 cites W1971731852 @default.
• W1563220956 cites W1974359739 @default.
• W1563220956 cites W1974384388 @default.
• W1563220956 cites W1979933759 @default.
• W1563220956 cites W1980956528 @default.
• W1563220956 cites W1981190530 @default.
• W1563220956 cites W1981459575 @default.
• W1563220956 cites W1981630108 @default.
• W1563220956 cites W1982294671 @default.
• W1563220956 cites W1982632066 @default.
• W1563220956 cites W1983521962 @default.
• W1563220956 cites W1990765545 @default.
• W1563220956 cites W1991591937 @default.
• W1563220956 cites W1993636112 @default.
• W1563220956 cites W2000598063 @default.
• W1563220956 cites W2004551963 @default.
• W1563220956 cites W2010271765 @default.
• W1563220956 cites W2016687128 @default.
• W1563220956 cites W2020844317 @default.
• W1563220956 cites W2022682022 @default.
• W1563220956 cites W2024181715 @default.
• W1563220956 cites W2025703535 @default.
• W1563220956 cites W2029432385 @default.
• W1563220956 cites W2029653085 @default.
• W1563220956 cites W2031696070 @default.
• W1563220956 cites W2033771600 @default.
• W1563220956 cites W2041243517 @default.
• W1563220956 cites W2045494339 @default.
• W1563220956 cites W2049655180 @default.
• W1563220956 cites W2050996677 @default.
• W1563220956 cites W2053664177 @default.
• W1563220956 cites W2057129604 @default.
• W1563220956 cites W2057256502 @default.
• W1563220956 cites W2058471848 @default.
• W1563220956 cites W2060324329 @default.
• W1563220956 cites W2061904465 @default.
• W1563220956 cites W2063168217 @default.
• W1563220956 cites W2063474974 @default.
• W1563220956 cites W2066981371 @default.
• W1563220956 cites W2070111196 @default.
• W1563220956 cites W2072630093 @default.
• W1563220956 cites W2072729698 @default.
• W1563220956 cites W2074414186 @default.
• W1563220956 cites W2075318094 @default.
• W1563220956 cites W2075486195 @default.
• W1563220956 cites W2079870043 @default.
• W1563220956 cites W2080314348 @default.
• W1563220956 cites W2081627917 @default.
• W1563220956 cites W2082404092 @default.
• W1563220956 cites W2083101409 @default.
• W1563220956 cites W2087485028 @default.
• W1563220956 cites W2091733322 @default.
• W1563220956 cites W2094534317 @default.
• W1563220956 cites W2098325935 @default.
• W1563220956 cites W2103013123 @default.
• W1563220956 cites W2103804548 @default.
• W1563220956 cites W2104516446 @default.
• W1563220956 cites W2104827152 @default.
• W1563220956 cites W2105728388 @default.
• W1563220956 cites W2106491827 @default.
• W1563220956 cites W2106952837 @default.
• W1563220956 cites W2110319753 @default.
• W1563220956 cites W2110936141 @default.
• W1563220956 cites W2111105929 @default.
• W1563220956 cites W2111647749 @default.
• W1563220956 cites W2112214428 @default.
• W1563220956 cites W2112584618 @default.
• W1563220956 cites W2118910139 @default.
• W1563220956 cites W2119340803 @default.
• W1563220956 cites W2120802149 @default.
• W1563220956 cites W2122043569 @default.
• W1563220956 cites W2129253219 @default.

• next